{"id":"W2158134441","doi":"10.1200/jco.2006.07.9525","title":"Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":3859,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Gemcitabine; Erlotinib; Medicine; Internal medicine; Pancreatic cancer; Erlotinib Hydrochloride; Oncology; Hazard ratio; Adverse effect; Placebo; Clinical endpoint; Clinical trial; Cancer; Epidermal growth factor receptor; Confidence interval; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null}